| 1.46 0.02 (1.39%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 | 1-year : | 1.96 |
| Resists | First : | 1.56 | Second : | 1.67 |
| Pivot price | 1.43 |
|||
| Supports | First : | 1.38 | Second : | 1.15 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.43 |
| MA(100) : | 1.47  |
MA(250) : | 1.63 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.3 |
D(3) : | 57.7 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 2.25 | Low : | 1.22 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ UBX ] has closed below upper band by 14.4%. Bollinger Bands are 77.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.47 - 1.48 | 1.48 - 1.48 |
| Low: | 1.4 - 1.41 | 1.41 - 1.42 |
| Close: | 1.45 - 1.46 | 1.46 - 1.47 |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Tue, 24 Sep 2024
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - GlobeNewswire
Tue, 24 Sep 2024
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - StockTitan
Fri, 09 Aug 2024
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Tue, 06 Aug 2024
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates - StockTitan
Tue, 06 Aug 2024
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Mon, 22 Jul 2024
UNITY Biotechnology names new chief strategy officer - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 20.5 (%) |
| Shares Short | 302 (K) |
| Shares Short P.Month | 319 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.16 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -87.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.77 |
| PEG Ratio | 0 |
| Price to Book value | 1.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|